Research Article
The Potential Diagnostic Value of Exosomal Long Noncoding RNAs in Solid Tumors: A Meta-Analysis and Systematic Review
Table 1
Characteristics of the included studies.
| Author | Year | Country | Ethnic | Cancer type | lncRNA | Sample | Case | Control | TP | FP | FN | TN | Sensitivity (%) | Specificity (%) | QUADAS score |
| Qier L | 2014 | China | Asian | GC | LINC00152 | Plasma | 79 | 81 | 38 | 12 | 41 | 69 | 0.481 | 0.852 | 4 | Jiangting Wang | 2014 | China | Asian | LSCC | HOTAIR | Serum | 52 | 49 | 49 | 13 | 3 | 36 | 0.942 | 0.735 | 4 | Tong Liu | 2016 | China | Asian | CC | CRNDE-h | Serum | 148 | 160 | 104 | 15 | 44 | 145 | 0.703 | 0.904 | 4 | Xianxiu Ge | 2017 | China | Asian | CGC | ENST00000588480.1 | Serum | 35 | 56 | 22 | 15 | 13 | 41 | 0.629 | 0.732 | 3 | Rui Zhang | 2017 | China | Asian | NSCLC | MALAT-1 | Serum | 77 | 33 | 46 | 6 | 31 | 27 | 0.601 | 0.809 | 3 | Mei Xue | 2017 | China | Asian | BD | UCA1 | Serum | 30 | 30 | 24 | 5 | 6 | 25 | 0.800 | 0.833 | 4 | Huaying Dong | 2018 | China | Asian | BC | SNHG14 | Serum | 72 | 72 | 58 | 20 | 14 | 52 | 0.800 | 0.725 | 4 | Min Kang | 2018 | China | Asian | ESCC | PART1 | Serum | 79 | 79 | 62 | 11 | 17 | 68 | 0.786 | 0.865 | 2 | Li Sun | 2018 | China | Asian | HCC | LINC00161 | Serum | 56 | 56 | 42 | 15 | 14 | 41 | 0.750 | 0.732 | 5 | Jiansong Wang | 2018 | China | Asian | BC | H19 | Serum | 52 | 52 | 39 | 11 | 13 | 41 | 0.741 | 0.781 | 6 | Hong Xu | 2018 | China | Asian | HCC | ENSG00000258332.1 | Serum | 60 | 60 | 43 | 10 | 17 | 50 | 0.716 | 0.834 | 3 | Fatemeh Yazarlou | 2018 | Iran | Asian | BD | UCa1-201 | Urine | 59 | 24 | 44 | 4 | 15 | 20 | 0.754 | 0.812 | 4 | Fatemeh Yazarlou | 2018 | Iran | Asian | BD | UCa1-203 | Urine | 59 | 24 | 43 | 6 | 16 | 18 | 0.724 | 0.750 | 4 | Fatemeh Yazarlou | 2018 | Iran | Asian | BD | MalaT1 | Urine | 59 | 24 | 38 | 4 | 21 | 20 | 0.638 | 0.833 | 4 | Fatemeh Yazarlou | 2018 | Iran | Asian | BD | LinC00355 | Urine | 59 | 24 | 40 | 5 | 19 | 19 | 0.680 | 0.792 | 4 | Yao Zhan | 2018 | China | Asian | BD | MALAT1 | Urine | 104 | 104 | 75 | 16 | 29 | 88 | 0.721 | 0.846 | 4 | Yao Zhan | 2018 | China | Asian | BD | PCAT-1 | Urine | 104 | 104 | 75 | 19 | 29 | 85 | 0.721 | 0.817 | 4 | Yao Zhan | 2018 | China | Asian | BD | SPRY4-IT1 | Urine | 104 | 104 | 69 | 24 | 35 | 80 | 0.663 | 0.769 | 4 | Yao Zhan | 2018 | China | Asian | BD | MALAT1 | Urine | 80 | 80 | 63 | 26 | 17 | 54 | 0.787 | 0.675 | 4 | Yao Zhan | 2018 | China | Asian | BD | PCAT-1 | Urine | 80 | 80 | 57 | 16 | 23 | 64 | 0.712 | 0.800 | 4 | Yao Zhan | 2018 | China | Asian | BD | SPRY4-IT1 | Urine | 80 | 80 | 70 | 28 | 10 | 52 | 0.875 | 0.650 | 4 | Wei Zhang | 2018 | China | Asian | NSCLC | RP11-838N2.4 | Serum | 78 | 78 | 58 | 26 | 20 | 52 | 0.745 | 0.673 | 3 | Rui Zhao | 2018 | China | Asian | GC | HOTTIP | Serum | 126 | 120 | 88 | 18 | 38 | 102 | 0.698 | 0.85 | 3 | Rui Zheng | 2018 | China | Asian | BD | PTENP1 | Plasma | 50 | 60 | 33 | 9 | 17 | 51 | 0.654 | 0.842 | 3 | Yu-Hui Wang | 2018 | China | Asian | PSA | SAP30L-AS1 | Plasma | 34 | 30 | 21 | 5 | 13 | 25 | 0.611 | 0.821 | 5 | Yu-Hui Wang | 2018 | China | Asian | PSA | SChLAP1 | Plasma | 33 | 30 | 29 | 7 | 4 | 23 | 0.879 | 0.767 | 5 | Yun Teng | 2019 | China | Asian | LSCC | SOX2-OT | Plasma | 75 | 79 | 57 | 21 | 18 | 58 | 0.760 | 0.732 | 6 | Shujun Zhang | 2019 | China | Asian | BD | PCAT-1, UBC1, SNHG16 | Serum | 160 | 160 | 128 | 40 | 32 | 120 | 0.800 | 0.750 | 2 |
|
|
GC: gastric cancer; LSCC: laryngeal squamous cell carcinoma; CC: colorectal cancer; CGC: cholangiocarcinoma; NSCLC: nonsmall cell lung cancer; BD: bladder tumor; BC: breast cancer; ESCC: esophageal squamous cell carcinoma; HCC: hepatocellular carcinoma; PSA: prostate cancer; TP: true positivity; FP: false positivity; TN: true negativity; FN: false negativity.
|